What is Medterra?
Founded in 2017 and headquartered in Irvine, California, Medterra has established itself as a specialized manufacturer and retailer of high-quality cannabidiol (CBD) products. By focusing on rigorous quality control and transparent supply chain management, the company has carved out a distinct market position. Medterra operates at the intersection of consumer packaged goods and health-tech, leveraging its direct-to-consumer and retail distribution channels to meet the rising demand for wellness alternatives. The company's business model emphasizes product efficacy and regulatory compliance, which has been instrumental in its ability to attract institutional debt financing to support its enterprise-level growth objectives.
How much funding has Medterra raised?
Medterra has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.5M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.5M led by PPP
Key Investors in Medterra
PPP
Public-Private Partnership
What's next for Medterra?
With the recent infusion of capital, Medterra is well-positioned to accelerate its strategic roadmap, which likely includes deepening its market penetration and optimizing its distribution infrastructure. As the regulatory environment for CBD continues to evolve, the company's focus on institutional-grade manufacturing standards provides a competitive moat. Future growth will likely center on product diversification and the expansion of its retail footprint, ensuring that Medterra remains a leader in the wellness industry. The company's ability to secure debt financing suggests a stable cash flow profile and a clear path toward long-term operational sustainability in a high-growth market segment.
See full Medterra company page
